New pill targets tough cancers with DNA mutations
NCT ID NCT04905914
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This study tests an experimental pill called ATRN-119 in people with advanced solid tumors that have certain DNA repair mutations. The goal is to see if the drug is safe and can shrink tumors. About 132 participants will take the drug by mouth, and researchers will monitor side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
NEXT Oncology- San Antonio
San Antonio, Texas, 78229, United States
-
NEXT Oncology- Virginia
Fairfax, Virginia, 22031, United States
-
NEXT- Oncology Dallas
Irving, Texas, 75039, United States
-
University Hospitals, Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.